Table 1: Baseline characteristics of patients in the present study.

All patients, 
Patients with dual therapy,  Patients with triple therapy,   values (dual therapy versus triple therapy groups)

Gender, male/female102/8373/7329/100.011
Age, years56.2 ± 10.755.7 ± 11.258.2 ± 8.70.197
Previous treatment: naïve/relapse/null119/45/21102/26/1817/19/30.0043
(naïve versus non-naïve)
AST, IU/L57.1 ± 48.058.0 ± 48.753.9 ± 45.90.630
ALT, IU/L70.4 ± 64.771.0 ± 64.968.1 ± 64.80.800
γ-GTP, IU/L57.0 ± 66.756.4 ± 68.659.2 ± 59.80.816
Hemoglobin, g/dL14.1 ± 1.314.0 ± 1.214.6 ± 1.30.0070
Platelets, ×104/mm316.6 ± 5.616.8 ± 5.816.0 ± 5.10.434
Treatment response
 RVR, 421527<0.0001
 EVR, 996534<0.0001
 SVR/relapse/null104/39/4272/37/3732/2/5<0.0001
 IFNL4, ss469415590,
  major/minor/ND
117/61/793/48/524/13/20.944

Peginterferon plus ribavirin with or without telaprevir therapy was defined as triple or dual therapy, respectively. Null: null response; AST: aspirate aminotransferase; ALT: alanine aminotransferase; γ-GTP: γ-glutamyltransferase; RVR: rapid virological response; EVR: early virological response; SVR: sustained virological response.